Replimune Group SEC filings
Filter: All · 8-K · 10-Q · 10-K · Form 4
Results of operations and financial condition · Financial statements and exhibits
AI summary, unreviewedReplimune Reports Fiscal Q2 2027 Net Loss of $0.54 per Share, Narrower Than $0.79 Consensus, as TUDRIQEV Launches
Amendments to articles or bylaws; fiscal year change · Submission of matters to a vote of security holders · Financial statements and exhibits
Results of operations and financial condition · Financial statements and exhibits
Other events · Financial statements and exhibits
Other events · Financial statements and exhibits
Other events · Financial statements and exhibits
Other events · Financial statements and exhibits
Regulation FD disclosure · Financial statements and exhibits